Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR …
The introduction in 1998 of imatinib mesylate (IM) revolutionized management of patients
with chronic myeloid leukemia (CML) and the second generation of tyrosine kinase …
with chronic myeloid leukemia (CML) and the second generation of tyrosine kinase …
Evolution of acquired resistance to anti-cancer therapy
Acquired drug resistance is a major limitation for the successful treatment of cancer.
Resistance can emerge due to a variety of reasons including host environmental factors as …
Resistance can emerge due to a variety of reasons including host environmental factors as …
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
Most patients with chronic myeloid leukemia (CML) treated with imatinib will relapse if
treatment is withdrawn. We conducted a prospective clinical trial of imatinib withdrawal in 40 …
treatment is withdrawn. We conducted a prospective clinical trial of imatinib withdrawal in 40 …
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective …
FX Mahon, D Réa, J Guilhot, F Guilhot, F Huguet… - The lancet …, 2010 - thelancet.com
Background Imatinib treatment significantly improves survival in patients with chronic
myeloid leukaemia (CML), but little is known about whether treatment can safely be …
myeloid leukaemia (CML), but little is known about whether treatment can safely be …
Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have …
P Rousselot, A Charbonnier… - Journal of clinical …, 2014 - ascopubs.org
Purpose More than half of patients with chronic-phase chronic myelogenous leukemia (CP-
CML) in complete molecular response (CMR) experience molecular relapse after imatinib …
CML) in complete molecular response (CMR) experience molecular relapse after imatinib …
Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib
D Marin, A Bazeos, FX Mahon, L Eliasson… - Journal of clinical …, 2010 - ascopubs.org
Purpose There is a considerable variability in the level of molecular responses achieved
with imatinib therapy in patients with chronic myeloid leukemia (CML). These differences …
with imatinib therapy in patients with chronic myeloid leukemia (CML). These differences …
Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With …
Purpose We studied BCR-ABL1 transcript levels in patients with chronic myeloid leukemia in
chronic phase (CML-CP) at 3, 6, and 12 months after starting imatinib to identify molecular …
chronic phase (CML-CP) at 3, 6, and 12 months after starting imatinib to identify molecular …
How I treat CML blast crisis
R Hehlmann - Blood, The Journal of the American Society of …, 2012 - ashpublications.org
Blast crisis (BC) remains the major challenge in the management of chronic myeloid
leukemia (CML). It is now generally accepted that BC is the consequence of continued BCR …
leukemia (CML). It is now generally accepted that BC is the consequence of continued BCR …
Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis
H De Lavallade, JF Apperley, JS Khorashad… - Journal of Clinical …, 2008 - ascopubs.org
Purpose Imatinib is remarkably effective in treating newly diagnosed patients with chronic
myeloid leukemia (CML) in chronic phase (CP). To date, most of the available data come …
myeloid leukemia (CML) in chronic phase (CP). To date, most of the available data come …
Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy
AR Ibrahim, L Eliasson, JF Apperley… - Blood, The Journal …, 2011 - ashpublications.org
We studied the relation between adherence to imatinib measured with microelectronic
monitoring systems and the probabilities of losing a complete cytogenetic response (CCyR) …
monitoring systems and the probabilities of losing a complete cytogenetic response (CCyR) …